Orally Delivered Microencapsulated Live Probiotic Formulation Lowers Serum Lipids in Hypercholesterolemic Hamsters
Orally Delivered Microencapsulated Live Probiotic Formulation Lowers Serum Lipids in Hypercholesterolemic Hamsters
复制标题
DOI：
10.1089/jmf.2008.0166
复制
发表时间：
2009-04-01
影响因子：
2.4
通讯作者：
Prakash, Satya
中科院分区：
文献类型：
--
作者：
Bhathena, Jasmine;Martoni, Christopher;Prakash, Satya
血清胆固醇升高是冠状动脉疾病的主要危险因素。营养疗法，如益生菌已被建议管理胆固醇升高。本研究探讨了微囊化的阿魏酸酯酶产生的发酵乳杆菌11976（LF 11976）益生菌制剂的胆固醇和甘油三酯降低潜力。雄性Bio F1 B仓鼠被分配到两组，通过口服管饲法接受微胶囊益生菌制剂（含有12.51对数菌落形成单位/mL的LF 11976细胞）或安慰剂制剂（空）微胶囊，每天两次，持续18周。在研究期间，动物喂食高胆固醇饮食。18周后，灌胃微囊化益生菌制剂组的血清总胆固醇、低密度脂蛋白（LDL）胆固醇和致动脉粥样硬化指数分别比安慰剂对照组低21.36%、31.43%和32.59%（P <0.05）。组织学研究显示，与对照动物相比，用微囊化LF 11976治疗的动物中动脉粥样硬化病变的进展减少。在饮食诱导的高胆固醇血症仓鼠中，用微囊化的LF 11976制剂治疗产生血清总胆固醇、LDL胆固醇和血清甘油三酯水平的显著降低。研究结果表明，口服微囊化益生菌细胞制剂作为管理过量血清胆固醇和甘油三酯水平的功能性营养替代品的潜力。
Elevated serum cholesterol is a major risk factor for coronary artery disease. Nutritional therapies such as probiotics have been suggested to manage elevated cholesterol. This study investigates the cholesterol and triglyceride lowering potential of a microencapsulated feruloyl esterase-producing Lactobacillus fermentum 11976 (LF11976) probiotic formulation. Male Bio F1B hamsters were assigned to two groups to receive either the microcapsule probiotic formulation (containing LF11976 cells at 12.51 log colony-forming units/mL) or placebo formulation (empty) microcapsules, twice daily, by oral gavage for 18 weeks. For the duration of the study, animals were fed a hypercholesterolemic diet. Serum total cholesterol, low-density lipoprotein (LDL) cholesterol, and the atherogenic index were 21.36%, 31.43%, and 32.59% lower in the group gavaged with the microencapsulated probiotic formulation than in the placebo control group after 18 weeks (P < .05). Histology studies showed reduced progression of atherosclerotic lesions in animals treated with microencapsulated LF11976 as compared to control animals. Treatment with microencapsulated LF11976 formulation produces significant reductions in serum total cholesterol, LDL cholesterol, and serum triglyceride levels in diet-induced hypercholesterolemic hamsters. Findings suggest the potential of the oral microencapsulated probiotic cell formulation as a functional nutritional alternative for managing excessive serum cholesterol and triglyceride levels.